Literature DB >> 23519966

In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.

Karl B Scheidweiler1, David M Schwope1,2, Erin L Karschner1,2, Nathalie A Desrosiers1, David A Gorelick1, Marilyn A Huestis1.   

Abstract

BACKGROUND: Blood and plasma cannabinoid stability is important for test interpretation and is best studied in authentic rather than fortified samples.
METHODS: Low and high blood and plasma pools were created for each of 10 participants after they smoked a cannabis cigarette. The stabilities of Δ(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), 11-nor-9-carboxy-THC (THCCOOH), cannabidiol (CBD), cannabinol (CBN), THC-glucuronide, and THCCOOH-glucuronide were determined after 1 week at room temperature; 1, 2, 4, 12, and 26 (±2) weeks at 4 °C; and 1, 2, 4, 12, 26 (±2), and 52 (±4) weeks at -20 °C. Stability was assessed by Friedman test.
RESULTS: Numbers of THC-glucuronide and CBD-positive blood samples were insufficient to assess stability. In blood, 11-OH-THC and CBN were stable for 1 week at room temperature, whereas THC and THCCOOH-glucuronide decreased and THCCOOH increased. In blood, THC, THCCOOH-glucuronide, THCCOOH, 11-OH-THC, and CBN were stable for 12, 4, 4, 12, and 26 weeks, respectively, at 4 °C and 12, 12, 26, 26, and 52 weeks at -20 °C. In plasma, THC-glucuronide, THC, CBN, and CBD were stable for 1 week at room temperature, whereas THCCOOH-glucuronide and 11-OH-THC decreased and THCCOOH increased. In plasma, THC-glucuronide, THC, THCCOOH-glucuronide, THCCOOH, 11-OH-THC, CBN, and CBD were stable for 26, 26, 2, 2, 26, 12, and 26 weeks, respectively, at 4 °C and 52, 52, 26, 26, 52, 52, and 52 weeks, respectively, at -20 °C.
CONCLUSIONS: Blood and plasma samples should be stored at -20 °C for no more than 3 and 6 months, respectively, to assure accurate cannabinoid quantitative results.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519966      PMCID: PMC3844293          DOI: 10.1373/clinchem.2012.201467

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  27 in total

1.  Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures.

Authors:  S J Heishman; M A Huestis; J E Henningfield; E J Cone
Journal:  Pharmacol Biochem Behav       Date:  1990-11       Impact factor: 3.533

2.  Stability of delta-9-tetrahydrocannabinol in stored blood and serum.

Authors:  A S Wong; M W Orbanosky; V C Reeve; J D Beede
Journal:  NIDA Res Monogr       Date:  1982

3.  Production of identical retention times and mass spectra for {delta}9-tetrahydrocannabinol and cannabidiol following derivatization with trifluoracetic anhydride with 1,1,1,3,3,3-hexafluoroisopropanol*.

Authors:  Rebecca Andrews; Sue Paterson
Journal:  J Anal Toxicol       Date:  2012 Jan-Feb       Impact factor: 3.367

4.  Tetrahydrocannabinol stability in whole blood: plastic versus glass containers.

Authors:  A S Christophersen
Journal:  J Anal Toxicol       Date:  1986 Jul-Aug       Impact factor: 3.367

5.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Authors:  E Johansson; M M Halldin; S Agurell; L E Hollister; H K Gillespie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Stability of delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma.

Authors:  J R Johnson; T A Jennison; M A Peat; R L Foltz
Journal:  J Anal Toxicol       Date:  1984 Sep-Oct       Impact factor: 3.367

7.  Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users.

Authors:  P Kelly; R T Jones
Journal:  J Anal Toxicol       Date:  1992 Jul-Aug       Impact factor: 3.367

Review 8.  Acyl glucuronide drug metabolites: toxicological and analytical implications.

Authors:  Maria Shipkova; Victor William Armstrong; Michael Oellerich; Eberhard Wieland
Journal:  Ther Drug Monit       Date:  2003-02       Impact factor: 3.681

9.  Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man.

Authors:  D M Cocchetto; S M Owens; M Perez-Reyes; S DiGuiseppi; L L Miller
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.

Authors:  J E Lindgren; A Ohlsson; S Agurell; L Hollister; H Gillespie
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more
  9 in total

1.  Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol.

Authors:  Matthew J Smith; Eva C Alden; Amy A Herrold; Andrea Roberts; Dan Stern; Joseph Jones; Allan Barnes; Kailyn P O'Connor; Marilyn A Huestis; Hans C Breiter
Journal:  J Stud Alcohol Drugs       Date:  2018-05       Impact factor: 2.582

2.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

3.  Cannabis effects on driving lateral control with and without alcohol.

Authors:  Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; Russell S Pierce; David A Gorelick; Gary Gaffney; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2015-06-23       Impact factor: 4.492

4.  Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Authors:  Erin L Karschner; Madeleine J Swortwood; Jussi Hirvonen; Robert S Goodwin; Wendy M Bosker; Johannes G Ramaekers; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-06-11       Impact factor: 3.345

5.  An Atmospheric Pressure Chemical Ionization MS/MS Assay Using Online Extraction for the Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine.

Authors:  Jelena Klawitter; Cristina Sempio; Sophie Mörlein; Erik De Bloois; Jacek Klepacki; Thomas Henthorn; Maureen A Leehey; Edward J Hoffenberg; Kelly Knupp; George S Wang; Christian Hopfer; Greg Kinney; Russell Bowler; Nicholas Foreman; Jeffrey Galinkin; Uwe Christians; Jost Klawitter
Journal:  Ther Drug Monit       Date:  2017-10       Impact factor: 3.681

6.  In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis.

Authors:  Nathalie A Desrosiers; Dayong Lee; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-12-01       Impact factor: 4.142

7.  Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.

Authors:  Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; David A Gorelick; Gary Gaffney; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-08-10       Impact factor: 3.345

8.  Detecting and quantifying marijuana metabolites in serum and urine of 19 dogs affected by marijuana toxicity.

Authors:  Alyson H Fitzgerald; Yuntao Zhang; Scott Fritz; William H Whitehouse; Tamera Brabson; Lisa Pohlman; Natalia Cernicchiaro; Caroline Tonozzi; Steve Ensley
Journal:  J Vet Diagn Invest       Date:  2021-07-10       Impact factor: 1.569

9.  Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes.

Authors:  Xingxing Diao; Karl B Scheidweiler; Ariane Wohlfarth; Mingshe Zhu; Shaokun Pang; Marilyn A Huestis
Journal:  Forensic Toxicol       Date:  2016-03-28       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.